Evidence map›Paper›PMID 32821744›Full record

ReviewBurns & trauma2020

Microbiome in the setting of burn patients: implications for infections and clinical outcomes.

Silvia Corcione, Tommaso Lupia, Francesco G De Rosa, Host and Microbiota Interaction Study Group (ESGHAMI) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Registry-linked trialOpen access · diamondAbstract readReview
In one paragraph

Review in Burns & trauma, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07209007 (An Exploratory Study on the Dynamics of Microbiome Dysbiosis), which is not on this map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07209007 recruitingnot on this mapstarted 2025, after this paper: background citation

An Exploratory Study on the Dynamics of Microbiome Dysbiosis (Microbial Imbalance) in the Skin and Gut Microbiome of Burn Patients

TypeobservationalSponsorCho Yoon sooRan2025 to 2030Enrolled600ConditionsBurn Injuries, Skin Disease, Microbiome, Microbiome DysbiosisArmsNo Intervention: Observational Cohort
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. The dual role of the microbiome in chronic wound management.Cell communication and signaling : CCS · 2026
    Review
  3. Article
  4. Observational
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Challenges Facing Two Outbreaks of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024
    Article
  11. Pathophysiology of Severe Burn Injuries: New Therapeutic Opportunities From a Systems Perspective.Journal of burn care & research : official publication of the American Burn Association · 2024
    Review
  12. Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Evolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Silvia CorcioneDepartment of Medical Sciences, Infectious Diseases, University of Turin, Italy.ORCID 0000-0003-2949-4297
Tommaso LupiaDepartment of Medical Sciences, Infectious Diseases, University of Turin, Italy.
Francesco G De RosaDepartment of Medical Sciences, Infectious Diseases, University of Turin, Italy.
Host and Microbiota Interaction Study Group (ESGHAMI) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
University of Turin · ITTufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Burn damage can lead to a state of immune dysregulation that facilitates the development of infections in patients. The most deleterious impact of this dysfunction is the loss of the skin's natural protective barrier. Furthermore, the risk of infection is exacerbated by protracted hospitalization, urinary catheters, endotracheal intubation, inhalation injury, arterial lines and central venous access, among other mainstays of burn care. Currently, infections comprise the leading cause of mortality after major burn injuries, which highlights the improvements observed over the last 50 years in the care provided to burn victims. The need to implement the empirical selection of antibiotic therapy to treat multidrug-resistant bacteria may concomitantly lead to an overall pervasiveness of difficult-to-treat pathogens in burn centres, as well as the propagation of antimicrobial resistance and the ultimate dysregulation of a healthy microbiome. While preliminary studies are examining the variability and evolution of human and mice microbiota, both during the early and late phase burn injury, one must consider that abnormal microbiome conditions could influence the systemic inflammatory response. A better understanding of the changes in the post-burn microbiome might be useful to interpret the provenance and subsequent development of infections, as well as to come up with inferences on the prognosis of burn patients. This review aims to summarise the current findings describing the microbiological changes in different organs and systems of burn patients and how these alterations affect the risks of infections, complications, and, ultimately, healing.

Indexed as

BurnGut microbiomeLung microbiomeMicrobiomeMultidrug-resistant organismsSkin microbiome

Identifiers

PMID32821744
PMCPMC7428410
OpenAlexW3049152495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.